13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions
Become familiarised with pharmacodynamic drug interactions, get comprehensively informed about in vitro and vivo aspects of the ICH M12 drug interaction guidelines, build up knowledge on biomarkets for detecting clinical DDIs and hear the latest update on FDA scientific efforts.
Dr Jorg Taubel, CEO ofRichmond Pharmacology will be attending.
Richmond Pharmacology Appoints John Hotti as Chief Technology Officer
April 22, 2026
Richmond Pharmacology is pleased to announce the appointment of John Hotti as Chief Technology Officer (CTO), strengthening the company’s leadership in technology-enabled clinical research.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.